The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non–small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901).
 
Si-Yang Maggie Liu
No Relationships to Disclose
 
Qing Zhou
Honoraria - AstraZeneca; Lilly; Pfizer; Roche; Sanofi
 
Hong-Hong Yan
No Relationships to Disclose
 
Gan Bin
No Relationships to Disclose
 
Ming-Yi Yang
No Relationships to Disclose
 
Jia-Yi Deng
No Relationships to Disclose
 
Hai-Yan Tu
No Relationships to Disclose
 
Xuchao Zhang
No Relationships to Disclose
 
Jian Su
No Relationships to Disclose
 
Jinji Yang
No Relationships to Disclose
 
Yi-Long Wu
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)